Amicus Therapeutics, Inc. (FOLD) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts FOLD Hot Sheet
Join SI Premium – FREE
Amicus Therapeutics, Inc. (NASDAQ: FOLD) reported Q4 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $922 thousand, versus the consensus estimate of $6.06 million.
For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.
For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AI chip sell-off is ‘unmoored from fundamentals,’ LYNX says
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
